Publication:
Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients

Simple item page
dc.contributor.authorIdilman, R.
dc.contributor.authorCinar, K.
dc.contributor.authorSeven, GÜLSEREN
dc.contributor.authorBozkus, Y.
dc.contributor.authorElhan, A.
dc.contributor.authorBozdayi, M.
dc.contributor.authorYurdaydin, C.
dc.contributor.authorBahar, K.
dc.contributor.institutionauthorSEVEN, GÜLSEREN
dc.date.accessioned2021-01-22T20:59:30Z
dc.date.available2021-01-22T20:59:30Z
dc.date.issued2012-03-01T00:00:00Z
dc.description.abstract. The aims of this study were to assess hepatitis B surface antigen (HBsAg) seroconversion and to determine its impact on the natural course of the disease in patients with HBeAg-negative chronic hepatitis B (CHB) during lamivudine (LMV) treatment. A total of 183 consecutive patients with HBeAg-negative CHB who were treated with LMV were included in the study. Data were retrospectively collected from outpatient visit charts. The primary endpoint was HBsAg seroconversion to anti-HBs. The secondary endpoint was to determine the development of cirrhosis. Loss of HBsAg was confirmed in 10 patients and seroconversion to anti-HBs in nine patients during LMV treatment or after its discontinuation. HBsAg seroconversion was achieved on-treatment in four patients after a median treatment duration of 30 months and off-treatment in the remaining five patients in a median 61 months after LMV discontinuation. The cumulative probability of HBsAg seroconversion increased from 0.6% at 1 year and 1.9% at 5 years to 21.5% at 10 years of LMV during and after LMV treatment. HBsAg clearance was preceded by undetectable serum hepatitis B virus (HBV) DNA. The majority of the patients responding to treatment had undetectable HBV DNA levels at 24 weeks of treatment. The cumulative probability of LMV resistance increased from 2.2% at 1 year to 37.3% at 5 years. No baseline parameter predicting either HBsAg seroconversion or the emergence of LMV resistance was identified. None of the patients with HBsAg seroconversion experienced virological breakthrough or disease progression during the follow-up period. These results indicate that HBsAg seroclearance can occur in patients with HBeAg-negative CHB under LMV therapy and predicts better clinical outcome.
dc.identifier.citationIdilman R., Cinar K., Seven G., Bozkus Y., Elhan A., Bozdayi M., Yurdaydin C., Bahar K., -Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients-, JOURNAL OF VIRAL HEPATITIS, cilt.19, ss.220-226, 2012
dc.identifier.doi10.1111/j.1365-2893.2011.01542.x
dc.identifier.scopus84857368049
dc.identifier.urihttp://hdl.handle.net/20.500.12645/28135
dc.identifier.wosWOS:000300502500009
dc.titleHepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients
dc.typeArticle
dspace.entity.typePublication
local.avesis.ida150e914-ff54-48a2-81e9-d9e25f833e38
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational1
relation.isAuthorOfPublicationfedf47e7-d7dd-44db-ada5-60bbaef0ae5b
relation.isAuthorOfPublication.latestForDiscoveryfedf47e7-d7dd-44db-ada5-60bbaef0ae5b
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c
Files
Collections
Silinecekler